New Review and Meta-Analysis confirms weight gain with discontinuance of #Semaglutide and #Tirzepatide
Discontinuing GLP1 medications led to a pooled overall mean weight regain of 9.69 kg (or about 22 lbs in patients prescribed semaglutide/tirzepatide. The proportion of weight regained was proportional to the amount originally lost.
Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions, and should therefore be considered a chronic therapy to prevent weight regain and associated undesirable outcomes related to #Obesity.
#wegovy #ozempic #mounjaro #zepbound
https://onlinelibrary.wiley.com/doi/10.1111/obr.13929